Sight Sciences (NASDAQ:SGHT – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.
Valuation and Earnings
This table compares Sight Sciences and Pulmonx”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sight Sciences | $77.36 million | 7.58 | -$38.43 million | ($0.52) | -20.29 |
| Pulmonx | $90.50 million | 1.31 | -$54.00 million | ($1.01) | -2.69 |
Sight Sciences has higher earnings, but lower revenue than Pulmonx. Sight Sciences is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
55.5% of Sight Sciences shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 30.4% of Sight Sciences shares are held by company insiders. Comparatively, 7.5% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Sight Sciences and Pulmonx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sight Sciences | -32.13% | -43.91% | -22.20% |
| Pulmonx | -47.93% | -98.23% | -35.89% |
Analyst Recommendations
This is a summary of current recommendations for Sight Sciences and Pulmonx, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sight Sciences | 1 | 2 | 5 | 0 | 2.50 |
| Pulmonx | 1 | 0 | 3 | 1 | 2.80 |
Sight Sciences presently has a consensus price target of $10.31, indicating a potential downside of 2.25%. Pulmonx has a consensus price target of $7.50, indicating a potential upside of 175.74%. Given Pulmonx’s stronger consensus rating and higher probable upside, analysts clearly believe Pulmonx is more favorable than Sight Sciences.
Volatility & Risk
Sight Sciences has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500.
Summary
Sight Sciences beats Pulmonx on 9 of the 15 factors compared between the two stocks.
About Sight Sciences
Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.
About Pulmonx
Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company’s Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.
Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
